Investor Relations
Investor Relations
Company overview:
Incorporated: | January 2000 | ||
|---|---|---|---|
Stock exchange: | Alternext by NYSE-Euronext, Paris | ||
Ticker code: | ALCLS |
| |
ISIN code: | FR0010425595 | ||
Number of outstanding shares: | 9,579,037 (as of Dec. 2008) | ||
Listing date: | 7 February 2007 | ||
Activity: | Cellectis develops high-precision, high-performance systems for DNA surgery and cell reprogramming. | ||
Legal form: | French "Société Anonyme" (SA) with a Board of Directors. | ||
Chief Executive Officer: | André Choulika PhD |
Corporate HQ and laboratories:
Parc Biocitech 102, avenue Gaston Roussel F-93230 Romainville, France map >
Number of employees: 67 (including 53 R&D staff) as of January 15, 2009
Last update : 03/10/2010
©2010 Cellectis